Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical nano-liposomal amphotericin B 0.4% for onychomycosis
IRCT20150101020514N18Phase 2Completed
- Sponsor
- Center for Research and Training in Skin Diseases and Leprosy
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amphotericin b in onychomycosis, sponsored by Center for Research and Training in Skin Diseases and Leprosy. Primary endpoints: partial clinical response, effective clinical response and 2 more. Started Jun 2021; status: completed.
02
Drugs
amphotericin b
03
Conditions
onychomycosis
Beyond the preview
Go deeper on IRCT20150101020514N18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150101020514N18.